{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:17:11Z","timestamp":1791037031320,"version":"4.1.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T00:00:00Z","timestamp":1351036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0047993","type":"journal-article","created":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T21:19:30Z","timestamp":1351113570000},"page":"e47993","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer"],"prefix":"10.1371","volume":"7","author":[{"given":"Franziska","family":"Pern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bogdanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sch\u00fcrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"L\u00e4nger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"D\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,10,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"WD Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molonc.2010.04.006","article-title":"Triple-negative breast cancer: Present challenges and new perspectives","volume":"4(3)","author":"F Podo","year":"2010","journal-title":"Mol Oncol"},{"key":"ref3","first-page":"157","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol","volume":"24(2)","author":"S Badve","year":"2011"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-010-1148-9","article-title":"Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk","volume":"126(3)","author":"AI Phipps","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"WD Foulkes","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"DP Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"PC Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"A Tutt","year":"2010","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","article-title":"The prevalence of BRCA mutations among young women with triple-negative breast cancer","volume":"9","author":"SR Young","year":"2009","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, <etal>et al<\/etal>.. (2012) Prevalence of BRCA1 mutations among 403 women with triple negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat, Mar 21. [Epub ahead of print].","DOI":"10.1007\/s10549-012-2021-9"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/bjc.2012.31","article-title":"BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years","volume":"106","author":"L Robertson","year":"2012","journal-title":"Br J Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e38361","DOI":"10.1371\/journal.pone.0038361","article-title":"BRCA2 mutations and triple-negative breast cancer","volume":"7(5)","author":"P Meyer","year":"2012","journal-title":"PLoS ONE"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22(6)","author":"B Xia","year":"2006","journal-title":"Mol Cell"},{"key":"ref14","first-page":"7155","article-title":"PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A","volume":"106(17)","author":"SM Sy","year":"2009"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39(2)","author":"N Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","article-title":"A recurrent mutation in PALB2 in Finnish cancer families","volume":"446(7133)","author":"H Erkko","year":"2007","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-010-1290-4","article-title":"PALB2 mutations in German and Russian patients with bilateral breast cancer","volume":"126(2)","author":"N Bogdanova","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"E2176","DOI":"10.1002\/humu.21478","article-title":"Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer","volume":"32","author":"H Hellebrand","year":"2011","journal-title":"Hum Mutat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","volume":"71(6)","author":"S Casadei","year":"2011","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/0008-5472.CAN-09-2089","article-title":"BRD7, a subunit of SWI\/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription","volume":"70(6)","author":"MT Harte","year":"2010","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/ncb2038","article-title":"BRD7 is a candidate tumour suppressor gene required for p53 function","volume":"12(4)","author":"J Drost","year":"2010","journal-title":"Nat Cell Biol"},{"key":"ref22","first-page":"14280","article-title":"Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A","volume":"107(32)","author":"AE Burrows","year":"2010"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00279094","article-title":"A routine method for the establishment of permanent growing lymphoblastoid cell lines","volume":"73","author":"H Neitzel","year":"1986","journal-title":"Hum Genet"},{"key":"ref24","first-page":"266","article-title":"Therapeutic options for triple-negative breast cancers with defective homologous recombination","volume":"1796(2)","author":"J Jaspers","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PPO.0b013e3181cf01eb","article-title":"Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer","volume":"16(1)","author":"EA Comen","year":"2010","journal-title":"Cancer J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1373\/clinchem.2011.173963","article-title":"Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes","volume":"58(4)","author":"S Hollants","year":"2012","journal-title":"Clin Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/gyno.1998.5270","article-title":"Frequency of BRCA1 mutation 5382insC in German breast cancer patients","volume":"72(3)","author":"J Backe","year":"1999","journal-title":"Gynecol Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","article-title":"Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors","volume":"28","author":"JS Kwon","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmedgenet-2011-100006","article-title":"Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer","volume":"48(8)","author":"DG Evans","year":"2011","journal-title":"J Med Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-011-1433-2","article-title":"Relative contributions of BRCA1 and BRCA2 mutations to \u201ctriple-negative\u201d breast cancer in Ashkenazi Women","volume":"129(1)","author":"E Comen","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17(5)","author":"AM Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","article-title":"Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations","volume":"130","author":"S Bayraktar","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.26576","article-title":"Prevalence of BRCA Mutations in an Unselected Population of Triple-Negative Breast Cancer","volume":"118","author":"A Hartman","year":"2012","journal-title":"Cancer"},{"key":"ref34","first-page":"2011","article-title":"Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study","volume":"59","author":"JE Armes","year":"1999","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"SR Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","article-title":"Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type","volume":"10","author":"WD Foulkes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"SR Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"DP Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/0008-5472.CAN-11-3364","article-title":"19p13.1 is a triple-negative-specific breast cancer susceptibility locus","volume":"72(7)","author":"KN Stevens","year":"2012","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdq460","article-title":"Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population","volume":"22(4)","author":"O Lavie","year":"2011","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Heidemann S, Fischer C, Engel C, Fischer B, Harder L, <etal>et al<\/etal>.. (2012) Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat. 2012 Apr 26. [Epub ahead of print].","DOI":"10.1007\/s10549-012-2050-4"},{"key":"ref42","first-page":"6788","article-title":"Analysis of PALB2\/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A","volume":"104(16)","author":"M Tischkowitz","year":"2007"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","article-title":"The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype","volume":"15(9)","author":"T Heikkinen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Penkert J, Schlegelberger B, Steinemann D, Gadzicki D (2012) No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways. Fam Cancer, in press.","DOI":"10.1007\/s10689-012-9556-0"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0047993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:29:43Z","timestamp":1589020183000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0047993"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Peterlongo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,10,24]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0047993","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,24]]}}}